Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.
์ข
๋ชฉ ์ฝ๋ TTNP
ํ์ฌ ์ด๋ฆTitan Pharmaceuticals Inc
์์ฅ์ผJan 18, 1996
CEOMr. Weei Jye Chay
์ง์ ์- -
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃJan 18
์ฃผ์Suite 505
๋์SAN FRANCISCO
์ฆ๊ถ ๊ฑฐ๋์NASDAQ Capital Market Consolidated
๊ตญ๊ฐUnited States of America
์ฐํธ ๋ฒํธ94080
์ ํ14152444990
์น์ฌ์ดํธhttps://www.titanpharm.com/
์ข
๋ชฉ ์ฝ๋ TTNP
์์ฅ์ผJan 18, 1996
CEOMr. Weei Jye Chay
์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.

๋ฐ์ดํฐ ์์